Literature DB >> 11481291

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.

A King1, I Phillips.   

Abstract

The in vitro activity of daptomycin was assessed in comparison with that of vancomycin and penicillin against a wide range of Gram-positive aerobic clinical isolates. MICs were determined by an agar dilution method on Mueller-Hinton agar (NCCLS/EUCAST) and on Isotonic agar adjusted to contain 50 mg/L free calcium (BSAC). Both media were enriched with 5% horse blood for fastidious organisms. Daptomycin MICs for all 172 staphylococci, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus, were 0.03-0.5 mg/L. For 99 of the 100 enterococci (Enterococcus faecalis, n = 50; Enterococcus faecium, n = 50), including 37 vancomycin-resistant isolates, they were 0.25-2 mg/L. For all 108 beta-haemolytic streptococci, including Streptococcus pyogenes and Streptococcus agalactiae, daptomycin MICs were 0.016- 0.25 mg/L; for 101 alpha-haemolytic streptococci, including Streptococcus pneumoniae and 'viridans' streptococci, they were 0.016-2 mg/L. For miscellaneous vancomycin-resistant isolates including Lactobacillus spp., Lactococcus spp., Leuconostoc spp., Pediococcus spp. and isolates of Enterococcus casseliflavus and Enterococcus gallinarum, daptomycin MICs were 0.03-2 mg/L; MICs for the seven isolates of Listeria monocytogenes were 0.25-4 mg/L. There was little difference between the results on Mueller-Hinton agar and on supplemented Isotonic agar The discrepant results occasionally obtained tended to be one dilution higher on supplemented Isotonic agar. Daptomycin was active (MICs < or = 2 mg/L) against all the isolates tested with the exception of one isolate each of E. faecium and L. monocytogenes (MICs = 4 mg/L). Our results indicate that daptomycin MICs are independent of methicillin and vancomycin MICs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481291     DOI: 10.1093/jac/48.2.219

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria.

Authors:  Ingo Klare; Carola Konstabel; Sibylle Müller-Bertling; Rolf Reissbrodt; Geert Huys; Marc Vancanneyt; Jean Swings; Herman Goossens; Wolfgang Witte
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

4.  Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections.

Authors:  Andrew D G Van Praagh; Tongchuan Li; Shuxin Zhang; Anu Arya; Liping Chen; Xi-Xian Zhang; Shellie Bertolami; Lawrence I Mortin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.

Authors:  Catalin Iancu; Aoife Grainger; Des Field; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

6.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.

Authors:  Lodewijk Spanjaard; Christina M J E Vandenbroucke-Grauls
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

8.  Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.

Authors:  Jeff Alder; Tongchaun Li; Donghui Yu; Larry Morton; Jared Silverman; Xi-Xian Zhang; Ian Critchley; Grace Thorne
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.

Authors:  Valerie Laganas; Jeffrey Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.

Authors:  Jared A Silverman; Nancy G Perlmutter; Howard M Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.